Developer docs
API playgroundTry for free, no card

Search company profiles

PMV Pharmaceuticals

Full company profile

uuid0002qjn

Namestring
PMV Pharmaceuticals
Legal namestring
PMV Pharmaceuticals, Inc.
Websiteurl
pmvpharma.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

PMV Pharmaceuticals is a clinical-stage precision oncology biopharmaceutical company developing orally bioavailable small molecules that structurally correct mutated p53 proteins to restore their wild-type tumor suppressor function. Founded in 2013 by David Mack, Arnold Levine (who discovered p53 in 1979), and Thomas Shenk, the company is headquartered in Princeton, New Jersey and has been publicly traded on NASDAQ under the ticker PMVP since its IPO. The company's lead and wholly-owned asset is rezatapopt (PC14586), a first-in-class selective p53 reactivator that stabilizes the Y220C mutant protein by binding the small crevice created when tyrosine is substituted by cysteine at amino acid 220. PMV is running the Phase 2 PYNNACLE registrational trial in advanced solid tumors harboring the TP53 Y220C mutation, where interim data showed a 34% overall response rate across 103 evaluable patients and a 46% response rate in the ovarian cancer subset. The company has received FDA Fast Track designation for solid tumors with p53 Y220C mutation and Orphan Drug Designation in TP53 Y220C-positive ovarian cancer, and is planning an NDA submission in platinum-resistant/refractory ovarian cancer in Q1 2027.

The pipeline also includes an Investigator-Initiated Trial of rezatapopt combined with azacitidine in relapsed/refractory AML/MDS, and undisclosed discovery-stage programs targeting additional p53 hotspot mutations, signaling a platform-extension strategy beyond the lead asset. PMV's business model is pre-commercial: it generates no product revenue, has no approved drugs, and distributes its investigational therapy solely through clinical trial participation and an expanded access program for patients with life-threatening conditions who have exhausted available options. Revenue will be generated only upon future regulatory approval and commercial launch. The company is funded by a combination of historical venture rounds (most recent disclosed round in August 2020 totaling $70M) and public equity capital, with $112.9M in cash and marketable securities as of December 31, 2025 against a FY2025 net loss of $77.7M, and approximately 90.2% institutional ownership reflecting strong professional investor sponsorship heading into the planned NDA filing.

Short descriptiontext

PMV Pharmaceuticals is a clinical-stage precision oncology company developing rezatapopt (PC14586), a first-in-class oral small molecule that reactivates the p53 Y220C mutant tumor suppressor, targeting patients with advanced solid tumors and platinum-resistant ovarian cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
p53 targeted oncology, precision oncology drugs, small molecule therapeutics, cancer drug development, tumor suppressor reactivation
Industry3 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Therapeutics
Revenue model1 record
1Pre-revenue / Clinical-stage
TypeOne Time License
Description

PMV Pharmaceuticals is a clinical-stage biopharmaceutical company with no commercialized products. The company is focused on developing rezatapopt through clinical trials toward regulatory approval. Revenue will be generated from future drug sales upon FDA approval.

biospace.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PMV Pharmaceuticals is a clinical-stage precision oncology company developing orally bioavailable small molecule therapeutics that selectively reactivate mutant p53 tumor suppressor proteins. Its lead product rezatapopt (PC14586) is a first-in-class p53 Y220C reactivator designed to structurally correct the mutant protein and restore wild-type tumor suppressor function in patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation. The pipeline also includes combination regimens and additional p53 hotspot mutation programs in discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 34% overall response rate across 103 evaluable patients in Phase 2 PYNNACLE trial
+2 more records
Product overview1 text field

PMV Pharmaceuticals is a clinical-stage precision oncology company developing small-molecule p53 reactivator therapies. The company's lead product is rezatapopt (PC14586), a first-in-class selective p53 Y220C reactivator currently in Phase 2 registrational trials (PYNNACLE) for advanced solid tumors with tumor-agnostic indication. The pipeline also includes an Investigator Initiated Trial combining rezatapopt with azacitidine for AML/MDS, and additional undisclosed p53 hotspot mutation targets in discovery. PMV takes a unique approach to structurally correcting mutant p53 proteins to restore their wild-type tumor suppressor function.

Product and service3 records
1rezatapopt (PC14586)
Categoryprecision oncology therapeutics
Description

First-in-class selective p53 Y220C reactivator small molecule designed to be orally available for the treatment of patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation. The compound stabilizes the mutant p53 protein by binding the crevice created when tyrosine is substituted by cysteine at amino acid 220, restoring wild-type tumor suppressor function.

2rezatapopt and azacitidine combination (Investigator-Initiated Trial)
Categoryprecision oncology therapeutics
Description

Investigator-Initiated Trial combining rezatapopt with azacitidine for treatment of relapsed/refractory AML/MDS, evaluating rezatapopt in hematologic indications beyond the lead solid tumor program.

3Undisclosed p53 hotspot mutation targets (Discovery Pipeline)
Categoryprecision oncology therapeutics
Description

Pipeline candidates in discovery targeting additional undisclosed p53 hotspot mutations for treating various solid tumors, extending PMV's structural correction approach beyond the Y220C mutation.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor developing eprenetapopt (APR-246), another small molecule p53 reactivator targeting mutant p53 in cancer. Most directly comparable peer given shared mechanism of action and oncology focus.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapies targeting cancer resistance mechanisms. Comparable in stage, size, and small molecule oncology focus; PMV Clinical Advisory Board Chair Richard Heyman co-founded ORIC.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapies for genomically-defined cancers. Closely comparable in stage, indication focus, and small molecule approach; Kirsten Flowers (PMV board member) was previously Chief Commercial and Strategy Officer at Kura.

TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic lethality and targeted therapies. Comparable in stage, biomarker-driven approach, and small molecule modality; Tim Smith held business development roles at IDEAYA.

TypeBroad incumbent
Description

Developed precision oncology drugs including Krazati (adagrasib) for KRAS G12C-mutant cancers. Acquired by Bristol Myers Squibb in 2024 for ~$4.8B; serves as a benchmark for clinical-stage precision oncology M&A outcomes. Charles Baum (former Mirati CEO/President/Founder) sits on PMV's board.

TypeEmerging player
Description

Clinical-stage oncology company developing synthetic lethality-based therapies, including programs targeting p53-deficient cancers. Compares in cancer genetics focus and target identification approach; partial mechanistic overlap with PMV's p53 restoration strategy.

TypeEmerging player
Description

Clinical-stage oncology company targeting chromatin regulatory proteins, including programs relevant to p53 biology and tumor suppressor function. Comparable in oncology small molecule approach and emerging-stage profile.

TypeEmerging player
Description

Clinical-stage precision oncology company using motion-based drug design to develop small molecule therapies for genomically-defined cancers. Comparable in precision oncology approach, small molecule modality, and clinical stage profile.

TypeBroad incumbent
Description

Established precision oncology company developing kinase-targeted therapies (Ayvakit, Gavreto). Comparable as a benchmark for biomarker-driven oncology commercialization and a likely pharma-partner comparable.

TypeOthers
Description

Computational drug discovery platform company with internal oncology pipeline. Adjacent peer — provides enabling technology for structure-based small molecule design similar to PMV's structural correction approach to mutant p53.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PMV Pharmaceuticals

Precision Oncology Therapeuticspmvpharma.com

PMV Pharmaceuticals is a clinical-stage precision oncology company developing rezatapopt (PC14586), a first-in-class oral small molecule that reactivates the p53 Y220C mutant tumor suppressor, targeting patients with advanced solid tumors and platinum-resistant ovarian cancer.

What PMV Pharmaceuticals does

PMV Pharmaceuticals is a clinical-stage precision oncology biopharmaceutical company developing orally bioavailable small molecules that structurally correct mutated p53 proteins to restore their wild-type tumor suppressor function. Founded in 2013 by David Mack, Arnold Levine (who discovered p53 in 1979), and Thomas Shenk, the company is headquartered in Princeton, New Jersey and has been publicly traded on NASDAQ under the ticker PMVP since its IPO. The company's lead and wholly-owned asset is rezatapopt (PC14586), a first-in-class selective p53 reactivator that stabilizes the Y220C mutant protein by binding the small crevice created when tyrosine is substituted by cysteine at amino acid 220. PMV is running the Phase 2 PYNNACLE registrational trial in advanced solid tumors harboring the TP53 Y220C mutation, where interim data showed a 34% overall response rate across 103 evaluable patients and a 46% response rate in the ovarian cancer subset. The company has received FDA Fast Track designation for solid tumors with p53 Y220C mutation and Orphan Drug Designation in TP53 Y220C-positive ovarian cancer, and is planning an NDA submission in platinum-resistant/refractory ovarian cancer in Q1 2027.

The pipeline also includes an Investigator-Initiated Trial of rezatapopt combined with azacitidine in relapsed/refractory AML/MDS, and undisclosed discovery-stage programs targeting additional p53 hotspot mutations, signaling a platform-extension strategy beyond the lead asset. PMV's business model is pre-commercial: it generates no product revenue, has no approved drugs, and distributes its investigational therapy solely through clinical trial participation and an expanded access program for patients with life-threatening conditions who have exhausted available options. Revenue will be generated only upon future regulatory approval and commercial launch. The company is funded by a combination of historical venture rounds (most recent disclosed round in August 2020 totaling $70M) and public equity capital, with $112.9M in cash and marketable securities as of December 31, 2025 against a FY2025 net loss of $77.7M, and approximately 90.2% institutional ownership reflecting strong professional investor sponsorship heading into the planned NDA filing.

PMV Pharmaceuticals firmographics

Firmographics
Name
PMV Pharmaceuticals
Legal name
PMV Pharmaceuticals, Inc.
Website
https://pmvpharma.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
PMV Pharmaceuticals is a clinical-stage precision oncology company developing rezatapopt (PC14586), a first-in-class oral small molecule that reactivates the p53 Y220C mutant tumor suppressor, targeting patients with advanced solid tumors and platinum-resistant ovarian cancer.
Ownership category
akta.pro rank

PMV Pharmaceuticals industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • P53 targeted oncology
  • Precision oncology drugs
  • Small molecule therapeutics
  • Cancer drug development
  • Tumor suppressor reactivation

Where PMV Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

PMV Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-revenue / Clinical-stage: PMV Pharmaceuticals is a clinical-stage biopharmaceutical company with no commercialized products. The company is focused on developing rezatapopt through clinical trials toward regulatory approval. Revenue will be generated from future drug sales upon FDA approval.

Distribution channels2 records

Marketing channels2 records

PMV Pharmaceuticals product offering

Product offering

Core offering

PMV Pharmaceuticals is a clinical-stage precision oncology company developing orally bioavailable small molecule therapeutics that selectively reactivate mutant p53 tumor suppressor proteins. Its lead product rezatapopt (PC14586) is a first-in-class p53 Y220C reactivator designed to structurally correct the mutant protein and restore wild-type tumor suppressor function in patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation. The pipeline also includes combination regimens and additional p53 hotspot mutation programs in discovery.

Product overview

PMV Pharmaceuticals is a clinical-stage precision oncology company developing small-molecule p53 reactivator therapies. The company's lead product is rezatapopt (PC14586), a first-in-class selective p53 Y220C reactivator currently in Phase 2 registrational trials (PYNNACLE) for advanced solid tumors with tumor-agnostic indication. The pipeline also includes an Investigator Initiated Trial combining rezatapopt with azacitidine for AML/MDS, and additional undisclosed p53 hotspot mutation targets in discovery. PMV takes a unique approach to structurally correcting mutant p53 proteins to restore their wild-type tumor suppressor function.

Differentiator

Problem solved

Functional benefit

Products and services

  • rezatapopt (PC14586) First-in-class selective p53 Y220C reactivator small molecule designed to be orally available for the treatment of patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation. The compound stabilizes the mutant p53 protein by binding the crevice created when tyrosine is substituted by cysteine at amino acid 220, restoring wild-type tumor suppressor function.
  • rezatapopt and azacitidine combination (Investigator-Initiated Trial) Investigator-Initiated Trial combining rezatapopt with azacitidine for treatment of relapsed/refractory AML/MDS, evaluating rezatapopt in hematologic indications beyond the lead solid tumor program.
  • Undisclosed p53 hotspot mutation targets (Discovery Pipeline) Pipeline candidates in discovery targeting additional undisclosed p53 hotspot mutations for treating various solid tumors, extending PMV's structural correction approach beyond the Y220C mutation.

Quantifiable outcome

  • 34% overall response rate across 103 evaluable patients in Phase 2 PYNNACLE trial
  • +2 more outcomes

Companies that use PMV Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

PMV Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

PMV Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

PMV Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Aprea Therapeutics: Direct competitor developing eprenetapopt (APR-246), another small molecule p53 reactivator targeting mutant p53 in cancer. Most directly comparable peer given shared mechanism of action and oncology focus.
  • ORIC Pharmaceuticals: Clinical-stage precision oncology company developing small molecule therapies targeting cancer resistance mechanisms. Comparable in stage, size, and small molecule oncology focus; PMV Clinical Advisory Board Chair Richard Heyman co-founded ORIC.
  • Kura Oncology: Clinical-stage precision oncology company developing small molecule therapies for genomically-defined cancers. Closely comparable in stage, indication focus, and small molecule approach; Kirsten Flowers (PMV board member) was previously Chief Commercial and Strategy Officer at Kura.
  • IDEAYA Biosciences: Clinical-stage precision oncology company developing synthetic lethality and targeted therapies. Comparable in stage, biomarker-driven approach, and small molecule modality; Tim Smith held business development roles at IDEAYA.

Broad incumbents

  • Mirati Therapeutics: Developed precision oncology drugs including Krazati (adagrasib) for KRAS G12C-mutant cancers. Acquired by Bristol Myers Squibb in 2024 for ~$4.8B; serves as a benchmark for clinical-stage precision oncology M&A outcomes. Charles Baum (former Mirati CEO/President/Founder) sits on PMV's board.
  • Blueprint Medicines: Established precision oncology company developing kinase-targeted therapies (Ayvakit, Gavreto). Comparable as a benchmark for biomarker-driven oncology commercialization and a likely pharma-partner comparable.

Emerging players

  • Tango Therapeutics: Clinical-stage oncology company developing synthetic lethality-based therapies, including programs targeting p53-deficient cancers. Compares in cancer genetics focus and target identification approach; partial mechanistic overlap with PMV's p53 restoration strategy.
  • Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin regulatory proteins, including programs relevant to p53 biology and tumor suppressor function. Comparable in oncology small molecule approach and emerging-stage profile.
  • Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design to develop small molecule therapies for genomically-defined cancers. Comparable in precision oncology approach, small molecule modality, and clinical stage profile.

Others

  • Schrödinger: Computational drug discovery platform company with internal oncology pipeline. Adjacent peer — provides enabling technology for structure-based small molecule design similar to PMV's structural correction approach to mutant p53.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

PMV Pharmaceuticals social profiles

Digital presence

PMV Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PMV Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles24 records

PMV Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PMV Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PMV Pharmaceuticals

What does PMV Pharmaceuticals do?

PMV Pharmaceuticals is a clinical-stage precision oncology company developing orally bioavailable small molecule therapeutics that selectively reactivate mutant p53 tumor suppressor proteins. Its lead product rezatapopt (PC14586) is a first-in-class p53 Y220C reactivator designed to structurally correct the mutant protein and restore wild-type tumor suppressor function in patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation. The pipeline also includes combination regimens and additional p53 hotspot mutation programs in discovery.

Is PMV Pharmaceuticals a public or private company?

PMV Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was PMV Pharmaceuticals founded?

PMV Pharmaceuticals was founded in 2013. It employs 51 to 100 people.

Where is PMV Pharmaceuticals based?

PMV Pharmaceuticals is headquartered in Princeton, United States, in the North America region.

How does PMV Pharmaceuticals make money?

One revenue line is on record: pre-revenue / Clinical-stage.

Who are PMV Pharmaceuticals's main competitors?

Direct peers on record are Aprea Therapeutics, ORIC Pharmaceuticals, Kura Oncology and IDEAYA Biosciences. Broad incumbents are Mirati Therapeutics and Blueprint Medicines. Emerging players are Tango Therapeutics, Foghorn Therapeutics and Relay Therapeutics. Schrödinger is listed as an others.

Does PMV Pharmaceuticals have an API?

No public API is recorded for PMV Pharmaceuticals.

What industry is PMV Pharmaceuticals in?

PMV Pharmaceuticals's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsPMV Pharmaceuticals (NASDAQ:PMVP) Cut to Sell at Wall Street ZenWall Street Zen downgraded PMV Pharmaceuticals from hold to sell. The stock opened at $1.26, with an average analyst rating of Moderate Buy and a target price of $4.33. The company reported a quarterly loss of $0.34 per share, beating the consensus estimate.GlobeNewswirePivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026PMV Pharmaceuticals announced updated results from the pivotal Phase 2 portion of the PYNNACLE trial of rezatapopt will be presented at ENA 2026. The presentation covers all trial cohorts, including efficacy, molecular activity, and safety. The trial evaluates rezatapopt in TP53 Y220C-positive advanced solid tumors.MarketBeatPMV Pharmaceuticals (NASDAQ:PMVP) Stock Lifted to Hold by Wall Street ZenWall Street Zen upgraded PMV Pharmaceuticals from Sell to Hold, while other analysts have mixed ratings. The stock has a consensus Moderate Buy rating with an average price target of $4.33. The company reported a loss of $0.34 per share for the quarter, beating estimates.MarketBeatPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Average Price Target of $4.33 According to AnalystsPMV Pharmaceuticals shares received a Moderate Buy rating from five analysts, with an average 12-month price target of $4.33. The stock traded down 2.7% to $1.27, and the company reported a Q2 loss of $0.34 per share, beating estimates. Analysts forecast a current-year loss of $1.26 per share.Seeking AlphaPMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer OpportunityPMV Pharmaceuticals' rezatapopt showed a 46% overall response rate in an interim study of heavily pretreated ovarian cancer patients with TP53 Y220C mutations, with median response duration of 10 months. The company expects to report pivotal data in Q4 2026 and file an NDA in Q1 2027. The stock is valued at $1.57, with a fair-value estimate of $3.50 to $4.Markets DailyPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Rated “Moderate Buy” by Wall Street AnalystsPMV Pharmaceuticals received an average analyst rating of "Moderate Buy" with a 12-month price target of $4.33. The stock opened at $1.78, and the company reported a quarterly loss of $0.34 per share, beating estimates of $0.39. Analysts forecast a current-year loss of $1.26 per share.Simply Wall StThese Biotech Stocks Are Cheap Based On 1 Fundamental MeasureThree biotech stocks—Optimi Health, PMV Pharmaceuticals, and NanoViricides—are highlighted for having P/B ratios below sector norms. Optimi Health reports CA$0.18 million revenue and rising MDMA shipments to Australian clinics, while PMV Pharmaceuticals trades at 1.5x P/B with Phase 2 data, and NanoViricides trades below peers despite no revenue.YahooShould You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?PMV Pharmaceuticals' stock crossed above its 200-day moving average, a golden cross, after a four-week gain of 9.7%. The stock sits at a Zacks Rank of #3, with earnings estimates revised up twice in 60 days, suggesting potential near-term gains.Investing.comPMV Pharma at H.C. Wainwright: rezafapt nears pivotal test By Investing.comPMV Pharma presented rezafapt data at H.C. Wainwright, showing a 46% overall response rate in 76 patients with platinum-resistant ovarian cancer. The company plans its first NDA in Q1 2025, expecting FDA approval and launch by end of 2025, with $154.4 million in available capital.Investing.comPMV Pharma at H.C. Wainwright: rezafapt nears pivotal test By Investing.comPMV Pharma presented rezafapt data at H.C. Wainwright, showing a 46% overall response rate in 76 patients with platinum-resistant ovarian cancer. The company plans its first NDA in Q1 2025, expecting FDA approval and launch by end of 2025, with $154.4 million in available capital.